Personalized Medicine

Dr. Stainthorpe emphasizes that oncologists should focus their efforts on treating the patient in a way that will produce the fewest side effects and greatest chance of survival. However, there may be times when cost should factor into the equation.

AR-V7 Predicts Chemotherapy Sensitivity in Metastatic Prostate Cancer

By Phoebe Starr

Personalized Medicine, Prostate Cancer, Solid Tumors

March 2015, Vol 6, No 2

Orlando, FL—Experts are hopeful that the field of prostate cancer will soon be catching up to breast cancer and some other tumor types with regard to genomic markers. A study featured at the 2015 Genitourinary Cancers Symposium suggests that the androgen receptor (AR) abnormality known as “AR-V7” will turn out to be a predictive marker to help in treatment selection for patients with metastatic castration-resistant prostate cancer (CRPC).

Foundation Medicine on a Molecular Level

Dr. Gary Palmer explains how Foundation Medicine is working to improve cancer therapies and personalized medicine on a molecular level.

Personalizing Cancer Treatment Based on a Unique Genetic Profile

Gary Palmer, MD, explains how research is ahead of the physician and patient and the need to educate the physician and patient on all the information about DNA and what drives the cancer.

Is Research Translating to Meaningful Treatment to Patients?

Dr. Palmer describes how the direct relationship between treatment directed to change in the DNA actually affects the outcome of patients.

How to Better Establish Clinical Utility for Tests in Personalized Medicine

Dr. Gary Palmer discusses the different profile of tumors and how to make findings as general as possible to better treat the patient.

Patients and Treatment Discussions

Dr. Gary Palmer explains the importance of patients having choices and the need to be involved in all discussions on treatment options.

Oncologists Show Low Genomic Confidence about the Use of Genetic Testing

By Laura Morgan

September 2014, Vol 5, No 7

Predictive multiplex genomic (or genetic) testing may revolutionize the treatment of cancer by identifying targetable mutations in cancer genes for their individual patients. Although genetic testing is commercially available, its use in clinical practice has not been fully investigated.

PD-1 Monoclonal Antibodies Usher in the Era of Immunotherapy in Oncology

By Dana Butler

Immunotherapy, Personalized Medicine

September 2014, Vol 5, No 7

Oncologists’ excitement about the promise of immunotherapy is about to be tested in clinical practice, with the recent FDA approval of pembrolizumab (Kytruda; Merck), the first anti–programmed death receptor-1 (PD-1) monoclonal antibody

Ramucirumab Improves Survival in Patients with Lung Cancer

By Dana Butler

Lung Cancer, Personalized Medicine, Solid Tumors

August 2014, Vol 5, No 6

Chicago, IL—When added to chemotherapy (ie, docetaxel), the new monoclonal antibody ramucirumab improved overall survival (OS) compared with chemotherapy alone in patients with stage IV non–small-cell lung cancer (NSCLC), according to phase 3 trial results presented at the 2014 American Society of Clinical Oncology meeting.